Get the Stockscreener App
13.91
1.83%
0.25
Theravance Biopharma Inc stock is traded at $13.91, with a volume of 846.06K.
It is up +1.83% in the last 24 hours and up +23.86% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$13.66
Open:
$13.75
24h Volume:
846.06K
Relative Volume:
2.91
Market Cap:
$700.53M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-15.12
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+5.78%
1M Performance:
+23.86%
6M Performance:
+49.33%
1Y Performance:
+73.66%
1-Day Range:
$13.65
$13.93
1-Week Range:
$13.18
$14.30
52-Week Range:
$7.88
$14.30
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
13.91 | 685.42M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance Biopharma reaches patent settlement with Cipla on YUPELRI inhalation - Investing.com
Does Theravance Biopharma Inc. qualify in momentum factor screeningJuly 2025 Rallies & Verified Entry Point Detection - Newser
Using data models to predict Theravance Biopharma Inc. stock movementJuly 2025 Technicals & Smart Allocation Stock Tips - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedWeekly Market Outlook & High Accuracy Buy Signal Tips - Newser
What’s the recovery path for long term holders of Theravance Biopharma Inc.2025 Support & Resistance & Low Risk Profit Maximizing Plans - Newser
Best data tools to analyze Theravance Biopharma Inc. stock2025 Volatility Report & Proven Capital Preservation Tips - Newser
Is Theravance Biopharma Inc. a momentum stock2025 Winners & Losers & Daily Technical Stock Forecast Reports - classian.co.kr
What earnings revisions data tells us about Theravance Biopharma Inc.2025 Volatility Report & AI Powered Buy/Sell Recommendations - Newser
Using Ichimoku Cloud for Theravance Biopharma Inc. technicals2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Theravance Biopharma Inc. stock undervalued right now2025 Market WrapUp & Low Risk Entry Point Tips - classian.co.kr
Tools to monitor Theravance Biopharma Inc. recovery probabilityJuly 2025 Action & Daily Profit Focused Stock Screening - Newser
How Theravance Biopharma Inc. stock performs during market volatilityJuly 2025 Setups & High Accuracy Investment Signals - Newser
Is Theravance Biopharma Inc. still worth holding after the dip2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Candlestick Signal Suggests Reversal in Theravance Biopharma Inc.2025 Volume Leaders & Real-Time Volume Analysis Alerts - metal.it
Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen - Defense World
What institutional flow reveals about Theravance Biopharma Inc.Weekly Investment Summary & Consistent Income Trade Ideas - Newser
Real time social sentiment graph for Theravance Biopharma Inc.2025 Top Decliners & AI Driven Price Predictions - Newser
Candlestick Reversal Detected on Theravance Biopharma Inc.’s ChartJuly 2025 Fed Impact & Reliable Volume Spike Alerts - metal.it
What makes Theravance Biopharma Inc. stock price move sharplyJuly 2025 Snapshot & Short-Term Trading Opportunity Alerts - thegnnews.com
H.C. Wainwright Maintains Buy Rating for Theravance Biopharma with $15 Price Target - AInvest
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
H.C. Wainwright Sticks to Their Buy Rating for Theravance Biopharma (TBPH) - The Globe and Mail
The 11% Return This Week Takes Theravance Biopharma's (NASDAQ:TBPH) Shareholders One-year Gains to 51% - 富途牛牛
Theravance Biopharma Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by XTX Topco Ltd - Defense World
Theravance Biopharma’s Earnings Call Highlights Strategic Gains - TipRanks
Theravance Biopharma, Inc. SEC 10-Q Report - TradingView
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Theravance Biopharma stock price target raised to $13 by Leerink Partners - Investing.com South Africa
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma stock price target raised to $13 by Leerink Partners By Investing.com - Investing.com Nigeria
Theravance Biopharma shares fall 1.85% premarket despite strong Q2 earnings and positive operational updates. - AInvest
Theravance Biopharma Q2 2025 Earnings Call Transcript - MarketBeat
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... - Yahoo Finance
Theravance Sales Jump 83 Percent - AOL.com
Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High Following Strong Earnings - Defense World
Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout - MSN
Technical signs of recovery in Theravance Biopharma Inc. [Analyst Upgrade]Free Safe Entry Momentum Stock Tips - Newser
Theravance Biopharma Reports Strong Q2 2025 Results - TipRanks
Theravance Biopharma: Hold Rating Amid Temporary Revenue Gains and Pipeline Uncertainty - TipRanks
Theravance Biopharma Reports Q2 2025 Results with 83.2% Revenue Growth, Exceeding Analyst Expectations - AInvest
Theravance Bio: Q2 Earnings Snapshot - Big Rapids Pioneer
Theravance Sales Jump 83 Percent - The Motley Fool
Theravance Biopharma (TBPH): A High-Conviction Play on Rare Disease Innovation and Durable Cash Flow - AInvest
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics - AInvest
Theravance Biopharma Expects $150M in Milestone Payments as CYPRESS Trial Approaches Pivotal Data Readout - AInvest
Theravance Biopharma's Q2 Surge: A Case Study in Biotech Resilience and Strategic Precision - AInvest
Earnings call transcript: Theravance Biopharma Q2 2025 earnings beat expectations - Investing.com
Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples - Investing.com Canada
Theravance Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):